In Segment A, contributors will get unique doses and schedules of oral ABBV-744 tablet to identify safe dosing program. Further participants will be enrolled within the determined monotherapy dosign regimen. In Section B, participants will acquire oral ruxolitinib and ABBV-744 is going to be given a